Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer

Acta Pharmacologica Sinica

Volumn 28, Issue 5, 2007, Pages 695-702

  Xu, Dao Hua ^a   Zhou, Chen Hui ^a   Xia, Yong Peng ^b   Qiu, Zong Ying ^b   Wu, Yu Zhang ^c   Jia, Zheng Cai ^c   Zhou, Wei ^c  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Epitope; Lipopeptide; Vaccine

Indexed keywords

CANCER VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 12; LIPOPEPTIDE; LIPOPEPTIDE 1; LIPOPEPTIDE 2; LIPOPEPTIDE 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TH2 CELL; TRANSGENIC MOUSE; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-12; LIPOPEPTIDES; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC;

EID: 34247588705     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00538.x     Document Type: Article

References (39)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 189 : 12 9.
2. Ljubojevic S. The human papillomavirus vaccine. Acta Dermatovenerol 2006 14 : 208.
3. Govan VA. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann N Y Acad Sci 2005 1056 : 328 43.
4. Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990 64 : 519 26.
5. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991 88 : 110 4.
6. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, De Cock KA, Ooms ME, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998 58 : 724 31.
7. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992 58 : 143 75.
8. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991 49 : 281 355.
9. Bona CA, Casares S, Brumeanu TD. Towards development of T-cell vaccine. Immunol Today 1998 19 : 126 33.
10. Bevan MJ. Helping the CD8+ T-cell response. Nat Rev immunol 2004 4 : 595 602.
11. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999 93 : 4309 17.
12. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002 106 : 113 21.
13. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human popillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002 169 : 350 8.
14. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997 27 : 1242 53.
15. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type I lipopeptide vaccine. J Virol 2000 74 : 1694 703.
16. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997 159 : 1383 92.
17. Shieh DC, Lin DT, Yang BS, Kuan HL, Kao KJ. High frequency of HLA-A0207 subtype in chinese population. Transfusion 1996 36 : 818 21.
18. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class I and promiscuous recognition by T cells. Eur J Immunol 1989 19 : 2237 42.
19. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998 4 : 2103 9.
20. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus(HPV) pep-tide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000 6 : 3406 16.
21. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J Immunol 1995 154 : 5934 43.
22. Loing E, Andrieu M, Thiam K, Schorner D, Wiesmuller KH, Hosmalin A, et al. Extension of HLA-A0201-restricted minimal epitope by N-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J Immunol 2000 164 : 900 7.
23. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 1999 5 : 2236 41.
24. Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, et al. Identification of HLA-A0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 2003 9 : 1850 7.
25. Wei WZ, Ratner S, Shibuya T, Yoo G, Jani A. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cell. J Immunol Methods 2001 258 : 141 50.
26. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J Exp Med 1994 179 : 1109 18.
27. Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004 64 : 2610 8.
28. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999 170 : 151 72.
29. Paul WE. Can the immune response control HIV infection Cell 1995 82 : 177 82.
30. Gras-Masse H. Single-chain lipopeptide vaccines for the induction virus-specific cytotoxic T cell responses in randomly selected populations. Mol Immunol 2001 38 : 423 31.
31. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA-A0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997 90 : 1751 67.
32. Mortara L, Gras-Masse H, Rommens C, Venet A, Guillet JG, Bourgault-Villada I. Type I CD4+ T cell help is required for induction of anti-peptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol 1999 73 : 4447 51.
33. Bessler WG, Mittenbuhler K, Esche U, Huber M. Lipopeptide adjuvants in combination treatment. Int Immunopharmacol 2003 3 : 1217 24.
34. Andrieu M, Loing E, Desoutter JF, Connan F, Choppin J, Gras-Masse H, et al. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8+ T lymphocyte activation. Eur J Immunol 2000 30 : 3256 65.
35. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003 77 : 1564 70.
36. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995 154 : 5071 9.
37. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigen. Immunol Rev 2004 199 : 9 26.
38. Mao YX, Chen YJ, Ge Y, Ma HB, Yu JF, Wu HY, et al. Recom-binant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro. Acta Pharmacol Sin 2006 27 : 741 6.
39. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998 393 : 474 8.